Patents by Inventor Jae Ryoung Hwang

Jae Ryoung Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of C-terminal domain of IGFBP-5 comprising heparin-binding domain as an angiogenesis inhibitor
    Patent number: 9072707
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: July 7, 2015
    Assignee: Research & Business Foundation Sungkyunkwan University
    Inventor: Jae Ryoung Hwang
  • NOVEL USE OF C-TERMINAL DOMAIN OF IGFBP-5 COMPRISING HEPARIN-BINDING DOMAIN AS AN ANGIOGENESIS INHIBITOR
    Publication number: 20140100160
    Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating cancer using the peptide, a novel angiogenesis-inhibiting peptide derived from heparin-binding domain of IGFBP-5, a polynucleotide encoding the peptide, an expression vector comprising the polynucleotide and a transformant comprising the vector.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 10, 2014
    Applicant: Research & Business Foundation Sungkyunkwan University
    Inventor: Jae Ryoung HWANG
  • TNF-? antagonists containing IGFBP5
    Patent number: 8552148
    Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNFR1.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: October 8, 2013
    Assignee: Sungkyunkwan University Foundation For Corporate Collaboration
    Inventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
  • CD9-specific human antibodies
    Patent number: 8197809
    Abstract: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: June 12, 2012
    Assignees: Korea Research Institute of Bioscience and Biotechnology, Sungkyunkwan University Foundation for Corporate Collaboration
    Inventors: Young Woo Park, So-Young Choi, Ji Hyun Park, Jung Yu, Eun-Jung Song, Sungsub Kim, Myeoung Hee Jang, Mi-Ju Park, Je-Ho Lee, Jae Ryoung Hwang
  • TNF-alpha Antagonists Containing IGFBP5
    Publication number: 20120046217
    Abstract: The present invention relates to: TNF-? antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-? antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-? overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.
    Type: Application
    Filed: June 30, 2009
    Publication date: February 23, 2012
    Applicant: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION
    Inventors: Je-Ho Lee, Jae-Ryoung Hwang, Jae-Ho Huh
  • CD9-SPECIFIC HUMAN ANTIBODIES
    Publication number: 20110195027
    Abstract: The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.
    Type: Application
    Filed: November 24, 2008
    Publication date: August 11, 2011
    Inventors: Young Woo Park, So-Young Choi, Ji Hyun Park, Jung yu, Eun-Jung Song, Sungsub Kim, Myeoung Hee Jang, Mi-Ju Park, Je-Ho Lee, Jae Ryoung Hwang